Listen on the go
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Download Slides
    Download Practice Aid
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Aleš Linhart

    Charles University and General University Hospital, Prague, Czech Republic

    Prof. Aleš Linhart, DSc, FESC, currently heads the Department of Cardiovascular Medicine at the First Medical Faculty and General University Hospital in Prague, Czech Republic. He serves as vice-dean for international affairs at the First Faculty of Medicine of Charles University in Prague. read more

    Prof. Linhart obtained his medical degree at Charles University, and received his training in cardiology and vascular medicine at General University Hospital and Broussais Hospital in Paris, France.

    In 2004 he was appointed professor at Charles University. His research focuses mainly on Fabry disease, metabolic cardiomyopathies, noninvasive cardiac imaging, and atherosclerosis. He is a member of several scientific societies, including the Czech Society of Cardiology and the European Society of Cardiology (ESC).

    Prof. Linhart served as the chairman of the Working Group on Myocardial and Pericardial Diseases of the ESC and is the immediate past-president of the Czech Society of Cardiology. He has authored or co-authored more than 450 scientific peer-reviewed papers, 85 book chapters, and three monographs.

    Prof. Aleš Linhart discloses: Advisory board and panel fees from Chiesi and Sanofi. Consultant fees from 4D Molecular Therapeutics, Amicus Therapeutics, Chiesi and Sanofi (relationship terminated). Grants/research support from Sanofi. Other financial or material support (royalties, patent, etc.) from Takeda (relationship terminated). Speaker’s Bureau fees from Amicus Therapeutics, Chiesi, Sanofi and Takeda.
    Dr Eric Wallace

    University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA

    Dr Wallace is a practising nephrologist and professor of medicine at the University of Alabama at Birmingham (UAB) School of Medicine in the USA, where he directs the UAB Rare Genetic Disease Clinic with a focus on Fabry disease. read more

    He became the medical director of telehealth for UAB in January 2017, given his work on telehealth for home dialysis in patients with rare diseases.

    Dr Wallace has earned numerous accolades, including the American Society of Nephrology Mid-Career Award. He has served as the principal investigator in numerous studies and clinical trials in Fabry disease. It is his goal to improve access to rare disease care across the USA by adding to the body of knowledge needed to treat patients and improving their access to care with telehealth.

    Dr Eric Wallace discloses: Advisory board or panel fees from Sanofi. Consultant fees from Amicus Therapeutics, Chiesi, Sanofi and Walking Fish Therapeutics. Other financial or material support (principal/sub investigator fees for sponsored clinical studies) from Natera and Sanofi.
    Prof. William Wilcox

    Emory University School of Medicine, Atlanta, GA, USA

    Prof. William Wilcox is a clinical, biochemical, and molecular geneticist in the Division of Medical Genetics at the Emory University School of Medicine in the USA. read more

    He specializes in the diagnosis and treatment of metabolic disorders and genetic disorders of the skeleton, particularly dwarfisms and limb deficiency disorders.

    Prof. Wilcox trained in paediatrics at the University of California, Los Angeles (UCLA) and then medical genetics in the UCLA Intercampus Medical Genetics Training Program. He was then a member of the UCLA paediatrics faculty based in the Medical Genetics Institute at Cedars-Sinai Medical Center in Los Angeles, until relocating to Emory in 2014.

    Prof. William Wilcox discloses: Advisory board or panel fees from BioMarin, Chiesi and Sanofi. Consultant fees from Relay Therapeutics, Spark Therapeutics and uniQure. Grants/research support from Amicus Therapeutics and Takeda. Salary/contractual service fees from Prevention Genetics (spouse) and Fulgent Diagnostics (spouse; relationship ended). Other financial or material support (principal/sub investigator fees for sponsored clinical studies) from 4D Molecular Therapeutics, Alexion, Amicus Therapeutics, BioMarin, Chiesi, Cyclo Therapeutics, Denali Therapeutics, Sangamo, Sanofi and Takeda.
    touchNEUROLOGY touchNEUROLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Neurometabolic Disease

    EUROPEAN PARTNER

    An Introduction to Neurometabolic Disease

    Advances in next-generation sequencing and next-generation metabolic screening have greatly improved diagnosis and increased our understanding of neurometabolic diseases. Novel neuroradiology techniques, such as diffusion-weighted imaging and proton MR spectroscopy, are also increasing our understanding of the disease mechanisms. Gene therapy is starting to fulfil its potential in the treatment of some neurometabolic disorders.

    Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Neurometabolic Disease Content

    Neurometabolic Disease
    Watch Time: 34 mins
    touchEXPERT OPINIONS
    The path from detection to personalized long-term care for Fabry disease
    CE/CME ACCREDITED Prof. Aleš Linhart, Dr Eric Wallace, Prof. William Wilcox Translations available:

    Fabry disease experts discuss early diagnosis, organ monitoring, long-term individualized care and future directions.

    Learning objectives
    Learning Objectives
    • Recognize the importance of early diagnosis and detection of organ involvement in Fabry disease in establishing an effective management plan for individual patients
    • Assess strategies for the long-term monitoring and follow-up of patients with Fabry disease for improved treatment adherence and quality of life
    • Discuss emerging therapeutic options and how they may change the future management of patients with Fabry disease
    Neuromuscular Diseases, Neurometabolic Disease
    Tahseen Mozaffar: PROPEL Study Results Investigating the use of AT-GAA for the Treatment of Late-onset Pompe Disease

    touchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease. Questions: Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15) What is AT-GAA […]

    Neurometabolic Disease
    Federico_T2.png
    Antonio Federico, EAN 2018 – Effects of migration on the pathophysiology of neurological conditions

    Antonio Federico (EAN Scientific Committee Chair; Professor, Clinical Neurology and Neurometabolic Diseases, University of Siena, Italy) describes the impact increased migration has had on the pathophysiology of neurological conditions and the need to increase awareness of this amongst neurologists. Questions 1. What has the increased migration of European people taught us about the pathophysiology of […]

    Neurometabolic Disease, Rare Diseases
    Federico_T.png
    Antonio Federico, EAN 2018 – Involvement of the EAN in rare neurological diseases

    Antonio Federico (EAN Scientific Committee Chair; Professor, Clinical Neurology and Neurometabolic Diseases, University of Siena, Italy) discusses the unique challenges that rare neurological diseases bring and how the EAN have a Task Force focused on this important area. Questions 1. Could you tell us a little about the Task Force within the EAN that is […]

    Neurometabolic Disease
    Deuschl_T2.png
    Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 2)

    Günther Deuschl (EAN President; Professor of Neurology, Department of Neurology, University Hospital Schleswig-Holstein, Kiel Campus, Germany) kindly took the time to discuss with us the burden of neurological diseases in Europe, including disparities across our continent, and how the EAN aims to help. Part 2 of 2. Questions 1. What are the unmet needs of […]

    Neurometabolic Disease
    Deuschl_T1.png
    Günther Deuschl, EAN 2018 – Burden of neurological diseases across Europe (Part 1)

    Günther Deuschl (EAN President; Professor of Neurology, Department of Neurology, University Hospital Schleswig-Holstein, Kiel Campus, Germany) kindly took the time to discuss with us the burden of neurological diseases in Europe, including disparities across our continent, and how the EAN aims to help. Part 1 of 2. Questions 1. What do you know about the […]

    Neurometabolic Disease
    Somboon_T.png
    Thapanee Somboon, AAN 2018 – Neurology and sleep-disordered breathing/sleep apnea

    Thapanee Somboon (Cleveland Clinic, OH) talks us through the key findings of her two presentations, which focused on the prevalence of high risk obstructive sleep apnea and insomnia in neurological populations (abstract available here) and the performance of sleep apnea screening tools in former professional athletes (abstract available here). Questions 1. How prevalent are obstructive […]

    Neurometabolic Disease
    13.jpg
    New Antisense Therapy in Development for Pompe Disease

    In this exclusive interview during WORLDSymposium 2015, Nicholas Clayton, MSc, staff scientist at Genzyme Corporation discusses the exciting new data he and his colleagues presented on antisense therapy that is in development to treat patients with Pompe disease.

    Neurometabolic Disease
    nmeta.png
    Niemann-Pick Disease Type C

    Dr. Marc Patterson a pediatric neurologist at Mayo Clinic discusses Niemann-Pick disease type C.

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchNEUROLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup